On June 27th, there were market rumors that the innovative drug, Wegovy, by Novo Nordisk, the 'magic weight loss medicine,' would have limited sales in China. On June 28th, Novo Nordisk China told reporters that since the approval of Novo Nordisk, it has officially launched the relevant process of drug supply according to plan, and will soon bring this heavyweight product into the Chinese market to benefit obese patients. Novo Nordisk has already listed in more than 10 countries worldwide. 'To meet the needs of patients, we are working hard to increase the supply of GLP-1 drugs. We will distribute existing product supplies in a responsible way in the global market, following consistent standards, focusing on ensuring the continuity of patient medication and the accessibility of innovative drugs.'
诺和诺德回应“减肥神药在华限量供应”：负责任的方式在全球市场分配现有产品供应
Novo Nordisk responds to "limited supply of weight loss miracle drug in China": Will distribute existing product supply in a responsible manner in global market.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.